|
1
|
Wen PY and Reardon DA: Neuro-oncology in
2015: Progress in glioma diagnosis, classification and treatment.
Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei X, Wang J, He J, Ma B and Chen J:
Biological characteristics of CD133(+) cancer stem cells derived
from human laryngeal carcinoma cell line. Int J Clin Exp Med.
7:2453–2462. 2014.PubMed/NCBI
|
|
3
|
Parajuli P, Anand R, Mandalaparty C,
Suryadevara R, Sriranga PU, Michelhaugh SK, Cazacu S, Finniss S,
Thakur A, Lum LG, et al: Preferential expression of functional
IL-17R in glioma stem cells: Potential role in self-renewal.
Oncotarget. 7:6121–6135. 2016.PubMed/NCBI
|
|
4
|
Najbauer J, Kraljik N and Németh P: Glioma
stem cells: Markers, hallmarks and therapeutic targeting by
metformin. Pathol Oncol Res. 20:789–797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yasumoto Y, Miyazaki H, Vaidyan LK, Kagawa
Y, Ebrahimi M, Yamamoto Y, Ogata M, Katsuyama Y, Sadahiro H, Suzuki
M and Owada Y: Inhibition of fatty acid synthase decreases
expression of stemness markers in glioma stem cells. PLoS One.
11:e01477172016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nie S, Gurrea M, Zhu J, Thakolwiboon S,
Heth JA, Muraszko KM, Fan X and Lubman DM: Tenascin-C: A novel
candidate marker for cancer stem cells in glioblastoma identified
by tissue microarrays. J Proteome Res. 14:814–822. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park EK, Lee JC, Park JW, Bang SY, Yi SA,
Kim BK, Park JH, Kwon SH, You JS, Nam SW, et al: Transcriptional
repression of cancer stem cell marker CD133 by tumor suppressor
p53. Cell Death Dis. 6:e19642015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tabu K, Sasai K, Kimura T, Wang L,
Aoyanagi E, Kohsaka S, Tanino M, Nishihara H and Tanaka S: Promoter
hypomethylation regulates CD133 expression in human gliomas. Cell
Res. 18:1037–1046. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren F, Sheng WQ and Du X: CD133: A cancer
stem cells marker, is used in colorectal cancers. World J
Gastroenterol. 19:2603–2611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Joo KM and Nam DH: Prospective
identification of cancer stem cells with the surface antigen CD133.
Methods Mol Biol. 568:57–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kievit FM, Florczyk SJ, Leung MC, Wang K,
Wu JD, Silber JR, Ellenbogen RG, Lee JS and Zhang M: Proliferation
and enrichment of CD133(+) glioblastoma cancer stem cells on 3D
chitosan-alginate scaffolds. Biomaterials. 35:9137–9143. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cutler MJ, Lowthers EL, Richard CL,
Hajducek DM, Spagnuolo PA and Blay J: Chemotherapeutic agents
attenuate CXCL12-mediated migration of colon cancer cells by
selecting for CXCR4-negative cells and increasing peptidase CD26.
BMC Cancer. 15:8822015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang
X, Wang L, Cao L, Hamid AS and Zhang G: Recombinant human decorin
suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco
Targets Ther. 5:143–152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guthrie HD, Welch GR, Cooper BS, Zakaria
AD and Johnson LA: Flow cytometric determination of degraded
deoxyribonucleic acid in granulosa cells to identify atretic
follicles during preovulatory maturation in the pig. Biol Reprod.
50:1303–1311. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamid AS, Li J, Wang Y, Wu X, Ali HA, Du
Z, Bo L, Zhang Y and Zhang G: Recombinant human decorin upregulates
p57KIP2 expression in HepG2 hepatoma cell lines. Mol Med
Rep. 8:511–516. 2013.PubMed/NCBI
|
|
18
|
Ffrench B, Gasch C, O'Leary JJ and
Gallagher MF: Developing ovarian cancer stem cell models: Laying
the pipeline from discovery to clinical intervention. Mol Cancer.
13:2622014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brescia P, Ortensi B, Fornasari L, Levi D,
Broggi G and Pelicci G: CD133 is essential for glioblastoma stem
cell maintenance. Stem Cells. 31:857–869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vescovi AL, Galli R and Reynolds BA: Brain
tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho DY, Lin SZ, Yang WK, Hsu DM, Lin HL,
Lee HC, Lee WY and Chiu SC: The role of cancer stem cells
(CD133(+)) in malignant gliomas. Cell Transplant. 20:121–125. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Sakariassen PØ, Tsinkalovsky O,
Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen
F, Stuhr L, et al: CD133 negative glioma cells form tumors in nude
rats and give rise to CD133 positive cells. Int J Cancer.
122:761–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brescia P, Richichi C and Pelicci G:
Current strategies for identification of glioma stem cells:
Adequate or unsatisfactory? J Oncol. 2012.3768942012.PubMed/NCBI
|
|
24
|
Sun T, Chen G, Li Y, Xie X, Zhou Y and Du
Z: Aggressive invasion is observed in CD133/A2B5+ glioma-initiating
cells. Oncol Lett. 10:3399–3406. 2015.PubMed/NCBI
|
|
25
|
Joo KM, Kim SY, Jin X, Song SY, Kong DS,
Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al: Clinical and
biological implications of CD133-positive and CD133-negative cells
in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Son MJ, Woolard K, Nam DH, Lee J and Fine
HA: SSEA-1 is an enrichment marker for tumor-initiating cells in
human glioblastoma. Cell Stem Cell. 4:440–452. 2009. View Article : Google Scholar : PubMed/NCBI
|
